Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

AGEN - Agenus Inc. Последние новости | Finranks

Home

/

AGEN

A

Agenus Inc. (AGEN)

NCM – Цена в реальном времени. Валюта: USD

7.06

+0.23 (3.37%)

Рынок открыт: Aug 12, 2026, 1:12 PM EDT

6.86

+0.03 (0.44%)

Предыдущая сессия: Aug 11, 2026, 7:47 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Agenus (AGEN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.05. This compares to a loss of $1 per share a year ago.

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and provided an update on its financing-supported strategy to advance botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, in a curative-intent treatment setting before surgery in high-risk, resectable microsatellite-stable (MSS) colon cancer. As previ.

Видео

No Data

There is no data to display

Пресс-релизы

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and provided an update on its financing-supported strategy to advance botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, in a curative-intent treatment setting before surgery in high-risk, resectable microsatellite-stable (MSS) colon cancer. As previ.